Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    NEXT STORY
    New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
    PREV STORY
    Teleflex Announces FDA Clearance for Expanded Indication of the UroLift® System for Treatment of Larger Prostates, Up to 100cc
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Reneo Pharmaceuticals Appoints Vineet R. Jindal as Chief Financial Officer

    author_avatar
    NASDAQ Market News

    Press release Oncology Venture establishes a convertible note program of 100 million SEK

    author_avatar
    NASDAQ Market News

    Scientific Article Covering Immune Modulating Interstitial Laser Thermotherapy by CLS’ Co-founder Professor Karl-Göran Tranberg Published in the Journal “Frontiers in Oncology”

    author_avatar
    NASDAQ Market News